Banque Cantonale Vaudoise Acquires 3,816 Shares of Natera, Inc. $NTRA

Banque Cantonale Vaudoise grew its holdings in Natera, Inc. (NASDAQ:NTRA) by 62.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,921 shares of the medical research company’s stock after acquiring an additional 3,816 shares during the period. Banque Cantonale Vaudoise’s holdings in Natera were worth $1,984,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. Horizon Investments LLC grew its position in shares of Natera by 22.0% during the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after purchasing an additional 44 shares in the last quarter. Sound Income Strategies LLC boosted its stake in Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after purchasing an additional 45 shares during the period. Savvy Advisors Inc. grew its holdings in Natera by 3.1% during the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after buying an additional 46 shares in the last quarter. Siemens Fonds Invest GmbH grew its holdings in Natera by 3.1% during the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock valued at $290,000 after buying an additional 54 shares in the last quarter. Finally, Alamea Verwaltungs GmbH raised its position in shares of Natera by 2.9% during the fourth quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company’s stock valued at $515,000 after buying an additional 62 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on NTRA. Robert W. Baird set a $265.00 target price on shares of Natera in a report on Friday, May 8th. Evercore reiterated an “outperform” rating and issued a $270.00 price target on shares of Natera in a report on Friday, May 8th. JPMorgan Chase & Co. boosted their price target on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Piper Sandler restated an “overweight” rating and set a $249.00 price objective on shares of Natera in a research report on Tuesday, May 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research report on Tuesday, April 21st. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $259.22.

Natera Trading Up 0.4%

Shares of NTRA stock opened at $261.91 on Friday. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $271.47. The stock has a fifty day simple moving average of $212.73 and a two-hundred day simple moving average of $215.87. The stock has a market capitalization of $37.51 billion, a price-to-earnings ratio of -160.68 and a beta of 1.56.

Insider Transactions at Natera

In related news, Director Roelof Botha sold 78,000 shares of Natera stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $220.31, for a total value of $17,184,180.00. Following the completion of the sale, the director directly owned 1,076,198 shares in the company, valued at $237,097,181.38. The trade was a 6.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Rowan E. Chapman sold 2,964 shares of the stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $216.78, for a total transaction of $642,535.92. Following the transaction, the director owned 3,124 shares in the company, valued at approximately $677,220.72. The trade was a 48.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 178,872 shares of company stock valued at $39,415,896 over the last three months. 5.05% of the stock is currently owned by corporate insiders.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.